A phase 1 study of ANAVEX 3-71, an oral small molecule agonist of SIGMAR1 and CHRM1, met its primary safety and secondary endpoint, Anavex Life Sciences recently announced. The drug is in development to treat neurodegenerative diseases and has previously been granted orphan drug designation by the FDA to treat frontotemporal dementia (FTD). The double-blind, randomized, placebo-controlled trial evaluated the safety, efficacy, and pharmacokinetics (PK) of oral escalating doses of ANAVEX 3-71 in evaluating in healthy patients.

Source: Anavex Life Sciences Corp.

Frontotemporal dementia (FTD) describes a cluster of neurocognitive syndromes that present with impairment of executive functioning, changes in behavior, and a decrease in language proficiency. FTD is the second most common form of dementia in those younger than 65 years and is expected to increase in prevalence as the population ages. FTD is a highly heritable disorder despite varying heritability among different clinical syndromes and subtypes due to various gene mutations. Up to 50% of FTD cases with autosomal-dominant inheritance report a family history of FTD. Clinical diagnoses include behavioral variant FTD (bvFTD); primary progressive aphasia (PPA), which affects language; and disorders that primarily affect movement, progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD).

• The annual prevalence of FTDs varies between 18 to 25 cases per 100,000 population in the USA.

However, the current Frontotemporal dementia (FTD) treatment market share, market uptake, and attribute analysis concerning the most potential emerging therapies (PR006, AL001, TRx0237, N-Acetyl-L-Leucine, PBFT02, etc.) have been provided under the market outlook section of the study covering 8 MM countries; The United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for Frontotemporal dementia (FTD) treatment. In the advanced development stage, the key companies are Prevail Therapeutics, Alector Inc., TauRx Therapeutics Ltd, IntraBio Inc, etc.

Based on solid domain and business knowledge, Thelansis Knowledge Partners has published the market outlook report on Frontotemporal dementia (FTD) to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2020 to 2030.

Thelansis specializes in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area, including rare / ultra-rare and mainstream indication. Over the period, we have built a robust repository of 6,000+ Bio-pharma reports that cover Epidemiology studies and Market forecasting based on the KOL opinions.

Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making

• Delivery Office:
  B-1030, C Wing Vrindavan tech village, Outer ring road
  Bangalore- 560037
  India+91(124)404-1731
  clientsupport@thelansis.com
• Sales office:
  183 Asylum Street Hartford,
  CT-06103, USA
  Contact no. +1 (302) 380-3552
  m.berg@thelansis.com